<i>In-vitro</i> proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report.

Anayama, Takashi; Taguchi, Mai; Tatenuma, Takehiro; Okada, Hironobu; Miyazaki, Ryohei; Hirohashi, Kentaro; Kume, Motohiko; Matsusaki, Keisuke; Orihashi, Kazumasa

In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report.

Anayama, Takashi; Taguchi, Mai; Tatenuma, Takehiro; Okada, Hironobu; Miyazaki, Ryohei; Hirohashi, Kentaro; Kume, Motohiko; Matsusaki, Keisuke; Orihashi, Kazumasa.

Afiliação

Anayama T; Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan. anayamat@kochi-u.ac.jp.
Taguchi M; Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan.
Tatenuma T; Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan.
Okada H; Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan.
Miyazaki R; Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan.
Hirohashi K; Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan.
Kume M; Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan.
Matsusaki K; Japanese CART Study Group, Kaname Second Clinic, Kanamecho Hospital, Tokyo 171-0043, Japan.
Orihashi K; Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan.

World J Clin Cases ; 7(23): 4036-4043, 2019 Dec 06.

Article em En | MEDLINE | ID: mdl-31832406

ABSTRACT

ABSTRACT

BACKGROUND:

We report the first case, to the best of our knowledge, of massive ascites due to recurrent malignant pleural mesothelioma that was controlled using KM-cell-free and concentrated ascites reinfusion therapy (KM-CART). The tumor cells derived via KM-CART were utilized secondarily in an in vitro cell growth assay using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) to investigate anticancer drug susceptibility. CASE

SUMMARY:

A 56-year-old man presented with recurrent malignant mesothelioma with massive ascites; more than 4000 mL of ascitic fluid was removed, filtered, and concentrated using KM-CART, and the cell-free ascitic fluid was reinfused into the patient to improve quality of life. Cancer cells isolated secondarily in an in vitro proliferation assay using CD-DST exhibited low sensitivity to pemetrexed and high sensitivity to gemcitabine. Treatment with gemcitabine maintained stable disease for 4 mo.